Professor Philip Rowlings
MBBS, FRACP, FRCPA, MS
Phil was elected to the Board as a Director in October 2016. He has over 30 years research experience in clinical trials of new treatments, biostatistical analyses of large datasets in blood and marrow transplant for leukaemia, multiple myeloma, lymphoma and other malignancies.
Professor Philip Rowlings has over 30 years research experience in clinical trials in Haematology. He has vast experience in biostatistical analyses of large datasets in blood and marrow transplant for leukaemia, multiple myeloma, lymphoma and other malignancies, as well as health resource utilisation. In the last 15 years he has also been involved in novel work in autologous bone marrow stem cell therapy for heart disease and genetic analyses in multiple myeloma, amongst other projects. He has been Director of Haematology for Calvary Mater Newcastle and Hunter New England Health District since 2010. His department has a large clinical trials department which usually contributes 5-10% of Australian totals of ALLG and other national trials, as well as piloting novel ALLG trials in AML.
Philip is a member of Scientific Advisory Committee of the Asia Pacific Bone Marrow Transplant (APBMT) group based in Ngoya, Japan. He is an executive member of NSW BMT advisory committee, a board member of the World Wide Blood and Marrow Transplant Network (WBMT), and served as a Scientific Director of the Center for International Blood and Marrow Transplant Research (CIBMTR, based in Milwaukee and Minneapolis, USA) from 1992-1998.
Philip has been an ALLG member since the mid-1980s participating in the early ALSG AML clinical trials. Following his return from the USA in 1998 he participated in the unification of the ALSG and ANZLG to become ALLG. He developed the initial operating procedures, and was the founding Chair of the ALLG Data Safety Monitoring Committee.